TY - JOUR
T1 - Erratum
T2 - Novel lipid-lowering therapies to reduce cardiovascular risk (JAMA (2021) 326:3 (266-267) DOI: 10.1001/jama.2021.2244)
AU - Wilkins, J. T.
AU - Lloyd-Jones, Donald M
N1 - Publisher Copyright:
© 2021 American Medical Association. All rights reserved.
PY - 2021/9/7
Y1 - 2021/9/7
N2 - Incorrect Classification of Pharmaceutical Agent: In the JAMA Insights article titled "Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk,"published July 20, 2021,1 therewas an error in nomenclature. Inclisiran is described as an antisense olignonucleotide, which is incorrect. Inclisiran is a small interfering RNA (siRNA) molecule that interferes with translation ofPCSK-9mRNA. This articlewas corrected online.
AB - Incorrect Classification of Pharmaceutical Agent: In the JAMA Insights article titled "Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk,"published July 20, 2021,1 therewas an error in nomenclature. Inclisiran is described as an antisense olignonucleotide, which is incorrect. Inclisiran is a small interfering RNA (siRNA) molecule that interferes with translation ofPCSK-9mRNA. This articlewas corrected online.
UR - http://www.scopus.com/inward/record.url?scp=85113464441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85113464441&partnerID=8YFLogxK
U2 - 10.1001/jama.2021.14278
DO - 10.1001/jama.2021.14278
M3 - Comment/debate
C2 - 34383011
AN - SCOPUS:85113464441
SN - 0098-7484
VL - 326
SP - 873
JO - JAMA - Journal of the American Medical Association
JF - JAMA - Journal of the American Medical Association
IS - 9
ER -